View item

US Department of Defense – Breast Cancer Research Program (BCRP) – Breakthrough Award Levels 3 and 4
Sponsor: US Department of Defense 		Closing Date: 24-Sep-2018
The Breast Cancer Research Program (BCRP) challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The BCRP has prepared a brief overview, The Breast Cancer Landscape, that describes what is currently known about the most pertinent topics that are consistent with the BCRP’s mission of ending breast cancer. Applicants are strongly urged to read and consider The Breast Cancer Landscape before preparing their applications.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:
• Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
• Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. Human clinical testing is required. PIs are expected to have experience in successfully leading large-scale projects.

Eligibility
• Independent investigators at all academic levels (or equivalent) are eligible to be named as PI.
• Each investigator may be named on only one Funding Level 3 pre-application and one Funding Level 4 pre-application as a PI or Initiating PI.

Key Mechanism Elements
• Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
• Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
• When submitting the pre-application, it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
• Clinical trials are allowed.
• There are no limitations on the number of applications for which an investigator may be named as a Partnering PI. However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
• Applications must include two or more breast cancer advocates on the research team.
• Submission of a preproposal is required; application submission is by invitation only.

Funding
Funding Level 3:
• Maximum funding of USD $2.5M for direct costs (plus indirect costs)
• Maximum period of performance is 4 years.
Funding Level 3 with Partnering PI Option:
• Maximum funding of USD $4M for direct costs (plus indirect costs)
• The maximum period of performance is 4 years.
Funding Level 4 and Funding Level 4 with Partnering PI Option:
• Maximum funding of USD $10M for direct costs (plus indirect costs)
• The maximum period of performance is 4 years.

Please see the U.S. Department of Defense Congressionally Directed Medical Research Program (CDMRP) website at http://cdmrp.army.mil/funding/bcrp and http://cdmrp.army.mil/bcrp/default for further information. Pre-applications are submitted via the CDMRP’s Electronic Biomedical Research Application Portal (EBRAP) and full applications are submitted via Grants.gov. For complete instructions for pre-applications and full applications, you must refer to both the Program Announcement and General Application Instructions documents.

Key Dates
Pre-applications due to UQR&I: 17 September 2018 (new date)
Pre-applications (mandatory) close with US Department of Defense: 24 September 2018 (new date)
Invitation from U.S. Department of Defense to submit a full application: 25 October 2018 (new date)
Invited full applications close with US Department of Defense: 13 December 2018 (new date)

Ahead of internal review, ensure all online components on EBRAP or Grants.gov are complete. To initiate review, email your completed Funding Application Coversheet to internationalgrants@research.uq.edu.au. Interested applicants are strongly encouraged to make contact with the UQR&I international team (via internationalgrants@research.uq.edu.au) well in advance of the UQR&I internal deadline to discuss their application.
Website: http://cdmrp.army.mil/funding/bcrp

Return